In addition, pioglitazone, an agonist of peroxisome proliferator-activated receptor α/γ (PPARα/γ) with the validated efficacy to relieve metabolic syndrome and steatosis [15], was administrated (1.2 mg/kg/day by gavage) as a positive control in a group of mice for the same period. This evidence concerns the gene PPARA and metabolic syndrome.